GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic control as well as weight loss in type II diabetes (T2DM) patients treated with GLP-1R agonists. This is a superior advantage of GLP-1R pharmaceuticals as many other drugs used to treat T2DM are weight neutral or actual cause weight gain. This review summarizes GLP-1R action on energy and glucose metabolism, the effectiveness of current GLP-1R agonists on weight loss in T2DM patients, as well as GLP-1R combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Unlike, GLP-1 and Gcg, GIP is not derived from preproglucagon and does not cause a reduction in body weight (Baggio and Drucker, 2007).”
BackgroundEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A Potential Decline in Life Expectancy in the United States in the 21st Century
Olshansky, S. J., Passaro, D. J., Hershow, R. C., Layden, J., Carnes, B. A., Brody, J., Hayflick, L., Butler, R. N., Allison, D. B., & Ludwig, D. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmsr043743 · Cited by 2,612
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 3×
“To further support a role for GLP-1R signaling in regulating food reward, recent fMRI studies in obese and obese T2DM patients have demonstrated that intravenous infusion of exenatide decreases the activation of brain regions involved in mediating food reward (van Bloemendaal et al., 2014).”
BackgroundResultA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“Both exenatide (DeFronzo et al., 2005; Heine et al., 2005; Moretto et al., 2008; Norris et al., 2009) and liraglutide (Astrup et al., 2009; Garber et al., 2009; Niswender et al., 2013; Lean et al., 2014) significantly improve glycemic control and cause a significant body weight loss in T2DM…”
BackgroundResultBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Cited by
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175
Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144
“It also delays gastric emptying and lowers food intake by promoting satiety.(25) GLP-1RAs have well-established glucose- and weight-lowering properties in patients with(23) and without(26) type 2 diabetes.”
BackgroundActivation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Gaykema, R. P., Newmyer, B. A., Ottolini, M., Raje, V., Warthen, D. M., Lambeth, P. S., Niccum, M., Yao, T., Huang, Y., Schulman, I. G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci81335 · Cited by 123
Zhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106
“GLP-1, a peptide hormone mainly synthetized and secreted by L-cells in guts, is essential for the regulation of glycometabolism.”
BackgroundInfluential
Metadata
- Authors
- Heppner, K. M., & Perez-Tilve, D.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-03-20
- Volume
- 9
- Pages
- 92-92
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2013557350
- Cited by
- 115
- References
- 49
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 based therapeutics: simultaneously combating T2DM and obesity. https://app.cochat.ai/papers/10.3389/fnins.2015.00092
- The paper
- Heppner, K. M., & Perez-Tilve, D. (2015). GLP-1 based therapeutics: simultaneously combating T2DM and obesity. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2015.00092
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.